Drug Notices
There is currently a national drug shortage of
National drug shortages that have resolved
- Trichloroacetic Acid (TCA) (Resolved May 11, 2022)
- For information on all current and resolved drug shortages and discontinuations reported to the U.S. Food & Drug Administration (FDA), please visit the FDA’s Drug Shortages page.
- Notify DSTDP (stdshortages@cdc.gov) of any shortage or low inventories of STI treatments in your jurisdiction so CDC can continue monitoring treatment availability.
Bicillin L-A® Shortage
The FDA has listed penicillin G benzathine injectable suspension products (Bicillin L-A®) on their drug shortage webpage, noting limited supply due to increased demand. The FDA website includes an expected duration for the shortage. CDC continues to monitor the situation and will post updates as needed.
Bicillin L-A® is the first-line recommended treatment for syphilis and the only recommended treatment option for some patients.
During this time, programs should:
- Continue to follow CDC’s treatment recommendations. Penicillin G benzathine (Bicillin L-A®) is the only recommended treatment for pregnant people infected with or exposed to syphilis.
- Doxycycline 100mg PO BID for two weeks (for early syphilis) or for four weeks (for late latent or syphilis of unknown duration) is an alternative for the treatment of non-pregnant people with a penicillin allergy.
- Prioritize the use of Bicillin L-A® to treat pregnant people and babies with congenital syphilis.
- To help CDC continue to monitor the situation, notify DSTDP (stdshortages@cdc.gov) of:
- Shortages or stock-outs of Bicillin L-A® in the jurisdiction.
- Situations in which patients diagnosed with syphilis are not being treated due to the inability to procure Bicillin L-A® in the jurisdiction.
- Report any shortages to the Pfizer Supply Continuity Team at 844-646-4398 (select 1 and then select 3).
STI Drug Availability as of July 29, 2022
Download Printable PDF
[PDF - 255 KB]
Medications
| FDA Drug Shortage List | Availability | Manufacturers * |
|---|---|---|
| No |
|
|
| FDA Drug Shortage List | Availability | Manufacturers * |
|---|---|---|
| No |
|
|
| FDA Drug Shortage List | Availability | Manufacturers * |
|---|---|---|
| Yes (as of 1/21/2022) |
|
|
1 https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Cefixime%20Oral%20Capsules&st=c&tab=tabs-1
* source: https://www.accessdata.fda.gov/scripts/cder/ndc/index.cfm
| FDA Drug Shortage List | Availability | Manufacturers * |
|---|---|---|
| No |
|
|
2 250 mg/500 mg vials
* source: https://www.accessdata.fda.gov/scripts/cder/ndc/index.cfm
| FDA Drug Shortage List | Availability | Manufacturers * |
|---|---|---|
| No |
|
|
3 100 mg tablet/capsule
* source: https://www.accessdata.fda.gov/scripts/cder/ndc/index.cfm
| FDA Drug Shortage List | Availability | Manufacturers * |
|---|---|---|
| Yes (as of 7/6/2022) |
|
|
4 https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Erythromycin%20Ophthalmic%20Ointment%20&st=c&tab=tabs-1
* source: https://www.accessdata.fda.gov/scripts/cder/ndc/index.cfm
| FDA Drug Shortage List | Availability | Manufacturers * |
|---|---|---|
| Yes (as of 7/23/2021) |
|
|
| FDA Drug Shortage List | Availability | Manufacturers * |
|---|---|---|
| Yes (as of 2/22/2012) |
|
|
6 https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm
* source: https://www.accessdata.fda.gov/scripts/cder/ndc/index.cfm
| FDA Drug Shortage List | Availability | Manufacturers * |
|---|---|---|
| No |
|
|
7 500mg tablet
* source: https://www.accessdata.fda.gov/scripts/cder/ndc/index.cfm